Log in

Masimo Stock Price, News & Analysis (NASDAQ:MASI)

$145.99
-0.19 (-0.13 %)
(As of 10/17/2019 09:10 AM ET)
Today's Range
$144.71
Now: $145.99
$147.39
50-Day Range
$142.12
MA: $149.73
$157.84
52-Week Range
$98.23
Now: $145.99
$160.25
Volume151,099 shs
Average Volume279,666 shs
Market Capitalization$7.79 billion
P/E Ratio48.18
Dividend YieldN/A
Beta1.19
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:MASI
CUSIP57479510
Phone949-297-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$858.29 million
Cash Flow$3.62 per share
Book Value$18.29 per share

Profitability

Net Income$193.54 million

Miscellaneous

Employees1,500
Market Cap$7.79 billion
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable

Receive MASI News and Ratings via Email

Sign-up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.


Masimo (NASDAQ:MASI) Frequently Asked Questions

What is Masimo's stock symbol?

Masimo trades on the NASDAQ under the ticker symbol "MASI."

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) announced its quarterly earnings results on Wednesday, July, 31st. The medical equipment provider reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.03. The medical equipment provider earned $229.60 million during the quarter, compared to analysts' expectations of $222.46 million. Masimo had a net margin of 22.15% and a return on equity of 17.82%. The company's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 earnings per share. View Masimo's Earnings History.

When is Masimo's next earnings date?

Masimo is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Masimo.

What guidance has Masimo issued on next quarter's earnings?

Masimo updated its FY19 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of $3.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.12. The company issued revenue guidance of $926.3 million, compared to the consensus revenue estimate of $919.94 million.

What price target have analysts set for MASI?

5 equities research analysts have issued 12-month target prices for Masimo's stock. Their predictions range from $134.50 to $180.00. On average, they expect Masimo's stock price to reach $160.50 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price. View Analyst Price Targets for Masimo.

What is the consensus analysts' recommendation for Masimo?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Masimo.

What are Wall Street analysts saying about Masimo stock?

Here are some recent quotes from research analysts about Masimo stock:
  • 1. According to Zacks Investment Research, "Masimo exited the first quarter on a robust note. The company continues to gain from its key Product segment, which witnessed solid growth in the quarter. Notably, the company’s non-invasive technology shipments surged in the quarter. Raised guidance for 2019 buoys optimism as well. Management is optimistic about Masimo’s recent initiative for hospital automation. The company recently launched its Iris Device Management System in the United States. Additionally, Masimo has launched Doctella to boost its remote care automation platform. Shares of Masimo outperformed the industry in a year’s time. Meanwhile, Masimo’s Royalty and Other segment witnessed significant softness in the quarter. In fact, management anticipates no meaningful contribution from the unit in 2019. Furthermore, Masimo expects foreign currency headwinds in 2019 to impact the top line. The company faces fierce competition from MedTech bigwigs." (5/8/2019)
  • 2. Needham & Company LLC analysts commented, "We hosted investor meetings with Kammerman, this week in the Midwest. We come away from the meetings with a better appreciation of MASI’s growth and margin outlook. We believe that MASI’s business model and product portfolio should enable it to sustain strong and consistent top and bottom line growth. Additionally, we think that the impact of the Philips agreement should cumulatively build as boards with MASI’s Rainbow and other measurements are installed in an increasing portion of Philips’ installed base. And we see several catalysts (detailed below) that could help MASI shares in 2019. Given all of this, we reiterate our Buy rating." (2/1/2019)

Has Masimo been receiving favorable news coverage?

News stories about MASI stock have trended very negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Masimo earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Masimo.

Are investors shorting Masimo?

Masimo saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 864,400 shares, an increase of 22.5% from the August 30th total of 705,500 shares. Based on an average trading volume of 338,900 shares, the days-to-cover ratio is currently 2.6 days. Approximately 1.8% of the shares of the stock are sold short. View Masimo's Current Options Chain.

Who are some of Masimo's key competitors?

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Walt Disney (DIS), Netflix (NFLX), Mastercard (MA), Paypal (PYPL), Alibaba Group (BABA), Visa (V), Twilio (TWLO), Arista Networks (ANET) and Shopify (SHOP).

Who are Masimo's key executives?

Masimo's management team includes the folowing people:
  • Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 54)
  • Mr. Micah Young, Exec. VP of Fin. & CFO (Age 40)
  • Mr. Anand Sampath, Chief Operating Officer (Age 53)
  • Dr. Steven J. Barker, Chairman of Scientific Advisory Board, Chief Science Officer & Director (Age 74)
  • Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 46)

Who are Masimo's major shareholders?

Masimo's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.39%), Pacer Advisors Inc. (0.03%), State of Alaska Department of Revenue (0.02%), Crossmark Global Holdings Inc. (0.01%), NewSquare Capital LLC (0.01%) and Diversified Trust Co (0.00%). Company insiders that own Masimo stock include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker and Yongsam Lee. View Institutional Ownership Trends for Masimo.

Which major investors are selling Masimo stock?

MASI stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Pacer Advisors Inc., First Hawaiian Bank and Crossmark Global Holdings Inc.. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker and Yongsam Lee. View Insider Buying and Selling for Masimo.

Which major investors are buying Masimo stock?

MASI stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Fox Run Management L.L.C., Carroll Financial Associates Inc., NewSquare Capital LLC, PFG Advisors and Diversified Trust Co. View Insider Buying and Selling for Masimo.

How do I buy shares of Masimo?

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Masimo's stock price today?

One share of MASI stock can currently be purchased for approximately $145.99.

How big of a company is Masimo?

Masimo has a market capitalization of $7.79 billion and generates $858.29 million in revenue each year. The medical equipment provider earns $193.54 million in net income (profit) each year or $3.03 on an earnings per share basis. Masimo employs 1,500 workers across the globe.View Additional Information About Masimo.

What is Masimo's official website?

The official website for Masimo is http://www.masimo.com/.

How can I contact Masimo?

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]


MarketBeat Community Rating for Masimo (NASDAQ MASI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  364 (Vote Underperform)
Total Votes:  727
MarketBeat's community ratings are surveys of what our community members think about Masimo and other stocks. Vote "Outperform" if you believe MASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel